[go: up one dir, main page]

EE200100472A - Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks - Google Patents

Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks

Info

Publication number
EE200100472A
EE200100472A EEP200100472A EEP200100472A EE200100472A EE 200100472 A EE200100472 A EE 200100472A EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 200100472 A EE200100472 A EE 200100472A
Authority
EE
Estonia
Prior art keywords
polypeptide
antibodies
oligonucleotide
poly
dna sequences
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/et
Publication of EE05497B1 publication Critical patent/EE05497B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
EE200100472A true EE200100472A (et) 2002-12-16
EE05497B1 EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (22)

Country Link
US (3) US7393651B2 (et)
EP (2) EP2292761A1 (et)
JP (2) JP4836329B2 (et)
CN (2) CN100469878C (et)
AT (1) ATE500328T1 (et)
AU (1) AU782139B2 (et)
BR (1) BR0008915A (et)
CA (1) CA2362896C (et)
CZ (1) CZ303128B6 (et)
DE (1) DE60045681D1 (et)
EE (1) EE05497B1 (et)
ES (1) ES2361905T3 (et)
HU (1) HU229376B1 (et)
IL (1) IL145310A0 (et)
IS (1) IS2819B (et)
MX (1) MXPA01009110A (et)
NO (1) NO333085B1 (et)
NZ (1) NZ514091A (et)
PL (1) PL207994B1 (et)
RU (1) RU2244748C2 (et)
WO (1) WO2000053749A2 (et)
ZA (1) ZA200107283B (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
EP2068928A2 (en) 2006-09-28 2009-06-17 Merck Serono SA Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP5815945B2 (ja) * 2007-08-06 2015-11-17 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸およびその使用
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
JP2001524814A (ja) * 1997-03-14 2001-12-04 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ２８種類のヒト分泌タンパク質
JP2002503955A (ja) * 1997-03-21 2002-02-05 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
ATE361933T1 (de) 1997-08-01 2007-06-15 Serono Genetics Inst Sa 5' ests für sekretierte proteine aus gehirngeweben
US20030044839A1 (en) 1997-09-17 2003-03-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
EP1141285A2 (en) * 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
CZ303128B6 (cs) 2012-04-18
CN1355843A (zh) 2002-06-26
JP2002537837A (ja) 2002-11-12
PL207994B1 (pl) 2011-02-28
US7393651B2 (en) 2008-07-01
US7670826B2 (en) 2010-03-02
US20050266426A1 (en) 2005-12-01
CN1637019A (zh) 2005-07-13
HU229376B1 (en) 2013-11-28
NZ514091A (en) 2004-01-30
HUP0200606A3 (en) 2004-11-29
JP2010233572A (ja) 2010-10-21
AU782139B2 (en) 2005-07-07
EP2292761A1 (en) 2011-03-09
JP4836329B2 (ja) 2011-12-14
DE60045681D1 (de) 2011-04-14
RU2244748C2 (ru) 2005-01-20
NO333085B1 (no) 2013-02-25
BR0008915A (pt) 2002-04-09
WO2000053749A3 (en) 2000-12-14
US20080274970A1 (en) 2008-11-06
ZA200107283B (en) 2002-12-24
CN100469878C (zh) 2009-03-18
NO20014417L (no) 2001-11-12
US20100267649A1 (en) 2010-10-21
IS2819B (is) 2012-12-15
EP1163337A2 (en) 2001-12-19
IL145310A0 (en) 2003-01-12
HUP0200606A2 (en) 2002-06-29
CA2362896A1 (en) 2000-09-14
ATE500328T1 (de) 2011-03-15
MXPA01009110A (es) 2002-08-20
WO2000053749A2 (en) 2000-09-14
HK1044169A1 (en) 2002-10-11
CA2362896C (en) 2012-07-31
ES2361905T3 (es) 2011-06-24
EE05497B1 (et) 2011-12-15
EP1163337B1 (en) 2011-03-02
US8143056B2 (en) 2012-03-27
IS6072A (is) 2001-09-10
PL350417A1 (en) 2002-12-16
AU4105100A (en) 2000-09-28
NO20014417D0 (no) 2001-09-11
CZ20013267A3 (cs) 2002-02-13

Similar Documents

Publication Publication Date Title
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
ATE335003T1 (de) Ret-ligand 3 (retl3), um neurales und renales wachstum zu stimulieren
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
ATE521702T1 (de) Krebsantigene und deren nutzung
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
EP0870036A4 (en) SYNTHETIC MAMMAL ALPHA-N-AECTYL GLUCOSAMINIDASE AND ENCODING GENETIC SEQUENCES THEREFOR
WO2000061750A3 (en) TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
DE50014417D1 (de) Nukleinsäure, die für ein protein der ctage-familie kodiert, deren verwendung und herstellung
EP1533378A3 (en) Tyrosine kinase substrate protein Tks7
WO2004043999A3 (en) Hsan ii related gene and expression products and uses thereof
MX9709747A (es) Serpina novedosa derivada de hipotalamo humano.

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313